Eli Lilly and Company (NYSE:LLY) Trading Down 1.6% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) fell 1.6% on Monday . The company traded as low as $978.87 and last traded at $988.76. 2,011,022 shares were traded during mid-day trading, a decline of 37% from the average session volume of 3,185,821 shares. The stock had previously closed at $1,004.92.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced the acquisition of Engage Biologics for up to $202 million, a move that expands its genetic-medicine capabilities and adds non-viral DNA delivery technology to its pipeline. Eli Lilly Buys Engage Biologics for Up to $202 Million
• Positive Sentiment: Recent results for Lilly’s oral GLP-1 candidate were viewed as encouraging, supporting the company’s growth story beyond injectable obesity drugs and reinforcing expectations for another large demand driver. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
• Positive Sentiment: Collaborative Drug Discovery partnered with Lilly to integrate Lilly TuneLab into CDD Vault, broadening access to Lilly’s AI/ML drug-discovery tools and highlighting continued R&D innovation. Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
• Positive Sentiment: Lilly’s R&D reputation was also supported by coverage noting that it topped prominent pharma innovation rankings, reinforcing the investment case around its pipeline execution. Eli Lilly tops prominent rankings on pharma R&D performance
• Negative Sentiment: Sentiment was partly offset by a new civil lawsuit in which Lilly accused several church leaders and businessmen of participating in a Trulicity rebate fraud scheme that allegedly cost the company more than $200 million, keeping legal and reimbursement risk in focus. Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
• Negative Sentiment: Another overhang came from the Supreme Court declining to hear Lilly’s appeal in a whistleblower case tied to Medicaid rebates, leaving a significant judgment and compliance concerns unresolved. Supreme Court Ruling Puts Eli Lilly Medicaid Risks And Dividend In Focus

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Guggenheim reiterated a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Finally, Bank of America cut their price objective on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,218.33.

Eli Lilly and Company Stock Down 0.5%

The company has a 50-day simple moving average of $940.54 and a 200-day simple moving average of $1,000.84. The firm has a market cap of $956.85 billion, a PE ratio of 36.09, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently made changes to their positions in the stock. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the period. M.E. Allison & CO. Inc. boosted its stake in shares of Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after purchasing an additional 10 shares during the period. Tanager Wealth Management LLP boosted its stake in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after purchasing an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after acquiring an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC raised its holdings in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after acquiring an additional 10 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.